Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.69 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26006164 | 0.89 | SLC15A2 (0.70) | SLC15A2SLC6A5FAAHCNR1CNR2 | |
| SCHEMBL15134134 | 0.89 | SLC15A2 (0.54) | SLC15A2SLC6A5FAAHCNR1CNR2 | |
| SCHEMBL15134133 | 0.86 | SLC15A2 (0.51) | SLC15A2SLC6A5FAAHCNR1CNR2 | |
| SCHEMBL29875979 | 0.85 | SLC15A2 (0.67) | SLC15A2SLC6A5FAAHCNR1CNR2 | |
| SCHEMBL30562710 | 0.84 | SLC6A5 (0.69) | SLC6A5ITGB3ITGA2BNOD1TLR2 | |
| SCHEMBL29941997 | 0.84 | SLC6A5 (0.69) | SLC6A5ITGB3ITGA2BNOD1TLR2 | |
| Acetic Acid SCHEMBL31293492 | 0.84 | SLC15A2 (0.65) | SLC15A2SLC6A5FAAHCNR1CNR2 | |
| SCHEMBL29942005 | 0.83 | SLC6A5 (0.51) | SLC15A2SLC6A5ITGB3ITGA2BNOD1 | |
| Acetic Acid SCHEMBL29453855 | 0.83 | SLC15A2 (0.59) | SLC15A2SLC6A5FAAHCNR1CNR2 | |
| SCHEMBL22462015 | 0.82 | SLC15A2 (1.00) | SLC15A2SLC6A5CPB2EPHX2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | MONASH UNIVERSITY (AU) | 2022-09-20 | — | — | US | disclosed |
| US-20200246487-A1 | NON-VIRAL GENE DELIVERY AGENT COMPRISING LIPOPEPTIDE (LP) COMPOUNDS | MONASH UNIVERSITY (AU) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | LNPEP, TLR9, LPXN | SLC15A2 1825/4885SLC6A5 4189/4885FAAH 2645/4885 |
| US-20200246487-A1 | NON-VIRAL GENE DELIVERY AGENT COMPRISING LIPOPEPTIDE (LP) COMPOUNDS | LNPEP, TLR9, LPXN | SLC15A2 1825/4885SLC6A5 4189/4885FAAH 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.